NasdaqHealth CareBiological Products, (No Diagnostic Substances)NEEDHAM, MA

Candel Therapeutics, Inc. CADL

Ask your AI

Estimated market cap $486.36M78.45M shares, shares as of Nov 5, 2026CIK 1841387

Insider trades, 12 mo

1 buy · 5 sells

$3.55M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

100

40.5% of shares · 44 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Candel Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Candel Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

6 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Sep 11, 2026. Insiders have two business days to file.

Recent insider trades

Paul Peter Tak Chief Executive Officer, Director	Sep 11 Form 4 ↗	Sale 10b5-1 plan	−$621.1K 59,379 sh @ $10.46	-39.9%
Paul Peter Tak Chief Executive Officer, Director	Sep 10 Form 4 ↗	Sale 10b5-1 plan	−$2.5M 220,866 sh @ $11.50	-44.8%
Seshu Tyagarajan Chief Technology Officer	Aug 17 Form 4 ↗	Sale 10b5-1 plan	−$84.0K 7,000 sh @ $12.00	-46.6%
Seshu Tyagarajan Chief Technology Officer	Jun 29 Form 4 ↗	Sale 10b5-1 plan	−$70.1K 7,000 sh @ $10.02	-42.0%
Francesca Barone Chief Scientific Officer	Jun 29 Form 4 ↗	Sale 10b5-1 plan	−$235.9K 23,447 sh @ $10.06	-42.0%

All CADL insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

31.78M shares

100 funds report CADL. Values checked against market prices.

Funds own 66% of shares (Q2 2026)

138 funds hold the stock.

Q3 2026: 41% · 5,560 of ~8,900 funds reported so far

Q2 202542%
Q3 202541%
Q4 202543%
Q1 202659%
Q2 202666%
Q3 2026 (so far)41%

Q3 2026. 21 new, 44 added to, 15 trimmed, 60 exited since Q2 2026.

Top 13F holders
#
1	FMR LLC 13F ↗	11.57M	$120.8M	+5.3%
2	BlackRock, Inc. 13F ↗	5.18M	$54.1M	+4.3%
3	State Street Corp 13F ↗	3.81M	$39.7M	+7.2%
4	Vanguard Capital Management LLC 13F ↗	2.95M	$30.8M	+9.4%
5	Geode Capital Management, LLC 13F ↗	1.71M	$17.8M	+8.6%
6	UBS Group AG 13F ↗	944,773	$9.9M	+458.1%
7	Kennedy Capital Management LLC 13F ↗	621,964	$6.5M	+27.4%
8	Vanguard Portfolio Management LLC 13F ↗	540,124	$5.6M	+23.6%
9	Vanguard Fiduciary Trust Co 13F ↗	492,575	$5.1M	+19.5%
10	Sands Capital Alternatives, LLC 13F ↗	405,837	$4.2M	unchanged

Download CSV Every fund that holds CADL, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Candel Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Candel Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2021	12	—	4.88M	$52.9M
Q4 2021	20	+8	6.95M	$54.4M
Q1 2022	23	+3	6.67M	$34.0M
Q2 2022	23	0	6.35M	$20.6M
Q3 2022	25	+2	6.08M	$19.1M
Q4 2022	21	-4	5.42M	$9.7M
Q1 2023	21	0	6.09M	$8.3M
Q2 2023	20	-1	5.37M	$6.8M
Q3 2023	20	0	5.26M	$4.9M
Q4 2023	22	+2	4.03M	$5.9M
Q1 2024	20	-2	3.78M	$6.0M
Q2 2024	45	+25	5.98M	$37.1M
Q3 2024	52	+7	6.70M	$46.4M
Q4 2024	71	+19	18.01M	$156.3M
Q1 2025	83	+12	21.19M	$119.7M
Q2 2025	78	-5	23.05M	$116.6M
Q3 2025	81	+3	22.69M	$115.7M
Q4 2025	84	+3	23.63M	$133.5M
Q1 2026	114	+30	43.43M	$212.9M
Q2 2026	138	+24	50.39M	$518.9M
Q3 2026	100	-38	31.78M	$331.8M

Each point is a quarter-end, from Q3 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (137404109). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes5 in 12 mo 8-K events4 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 4 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials5 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Candel Therapeutics, Inc.
Address: 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA 02494
Phone: 617-916-5445
Fiscal year ends: Dec 31
Filer category: emerging growth company
Incorporated in: DE
Listed as: CADL (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$6.20−$2.19 (−26.10%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $6.20 · High $9.49Nov 13, 2026

Aug 13, 2026Low $6.20 · High $13.75Nov 13, 2026

Nov 13, 2025Low $4.42 · High $13.75Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.